Anewtypeofosteoporosisdrugforpostmenopausalwomenathighriskforfractureshasreceivedapprovalfrom the U.S. Food and Drug Administration and Eu-ropean Commission. Prolia (denosumab; Amgen) is ahumanmonoclonalantibodydesignedtotargetRANKL,anosteoclastmaturationfactor.Thedrugmimicsosteo-protegerin,anaturallyoccurringproteinproducedbyos-teoblasts that acts as a decoy receptor for RANKL andhelps keep the balance of osteoblasts to osteoclasts incheck. The drug is delivered subcutaneously every 6months.
展开▼
